lopment and commercial rights for XIAFLEX in
Japan; and Actelion Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in
Canada,
Australia,
Brazil and Mexico. The sBLA for XIAFLEX for the treatment of Peyronie's disease was submitted to the FDA in November 2012. Additionally, collagenase clostridium histolyticum ("CCH") is in phase IIa of development for the treatment of Frozen Shoulder syndrome (adhesive capsulitis) and phase Ib of development for the treatment of cellulite (edematous fibrosclerotic panniculopathy). Auxilium also has rights to pursue additional indications for CCH. For additional information, visit
http://www.auxilium.com SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including statements made with respect to Auxilium's strategy, progress and timing of development programs and related trials, the efficacy of its product candidates, the commercial benefits available to it as a result of its agreements with third parties, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'
'/>"/>
SOURCE Auxilium Pharmaceuticals, Inc. Copyright©2012 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Auxilium Announces Appointments to Enhance Leadership Team2.
Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference3.
Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference4.
Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference5.
Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference6.
Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 20137.
Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting8.
Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie9.
Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication10.
MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock11.
FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner